Four AIM strugglers with recovery potential
Our award-winning AIM expert discusses how some of 2019’s worst performers could bounce back this year.
Read More
Faron Pharmaceuticals Oy – Interim results
TURKU – FINLAND, 23 September 2019 – Faron (AIM: FARN), the clinical stage biopharmaceutical company, today announces its unaudited interim results for the six months ended 30 June 2019 (the “Period”).
Faron Pharmaceuticals Oy – Final results from YODA study
Faron Pharmaceuticals Oy (AIM: FARN), the clinical stage biopharmaceutical company, today announces results from its pharmacokinetic/dynamic YODA study examining the administration of concomitant steroids and Traumakine in healthy volunteers.
Faron Pharmaceuticals Oy – Final Results
Faron Pharmaceuticals Ltd (AIM: FARN), the clinical stage biopharmaceutical company, today reports its full year audited results for the year ended 31 December 2018.
Faron Pharmaceuticals Ltd – Final Results
Faron Pharmaceuticals Ltd (AIM: FARN), the clinical stage biopharmaceutical company, today reports its full year audited results for the year ended 31 December 2017. Today, the Company also separately announced top line data from the Phase III INTEREST trial.